Gtree Pharmaceuticals Co., Ltd. was established in June 2014 for development and commercialization of new biopharmaceutical drugs. Currently, we are developing two new biopharmaceutical drugs: GBT-201, a treatment for ophthalmical diseases such as dry eye syndrome and Neurotrophic Keratopathy, and GBT-101, a treatment for dermal diseases such as Epidermolysis Bullosa using Thymosin beta 4 (Tβ4) in Korea and/or in the United States.
We seek to become an outstanding specialty biopharmaceutical company that is highly unique and strong in a niche worldwide market based on development and commercialization of first-in-class new drug with GBT-201 and GBT-101 in the U.S. and Pan Asia in the near future. Our purpose is to innovatively develop new first-in-class drugs.

ноутбук купить леновомихаил безлепкин органыOlikeкартридж совместимый черныйвзлом Facebook